CY1114326T1 - USE OF Leptin for the Treatment of Human Liposuction and the Method for Determining its Affiliation to a Therapeutic Treatment - Google Patents

USE OF Leptin for the Treatment of Human Liposuction and the Method for Determining its Affiliation to a Therapeutic Treatment

Info

Publication number
CY1114326T1
CY1114326T1 CY20131100389T CY131100389T CY1114326T1 CY 1114326 T1 CY1114326 T1 CY 1114326T1 CY 20131100389 T CY20131100389 T CY 20131100389T CY 131100389 T CY131100389 T CY 131100389T CY 1114326 T1 CY1114326 T1 CY 1114326T1
Authority
CY
Cyprus
Prior art keywords
leptin
treatment
affiliation
determining
analogs
Prior art date
Application number
CY20131100389T
Other languages
Greek (el)
Inventor
Alex M Depaoli
Elif Arioglu Oral
Simeon I Taylor
A Garg
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10165256.8A external-priority patent/EP2219031B1/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1114326T1 publication Critical patent/CY1114326T1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η λεπτίνη, τα ανάλογα και τα παράγωγα της χρησιμοποιούνται για τη θεραπευτική αντιμετώπιση ασθενών με λιποδυστροφία. Η λεπτίνη είναι αποτελεσματική εναντίον λιποδυστροφικών καταστάσεων που οφείλονται είτε σε γενετικές είτε σε επίκτητες μορφές της νόσου. Η χορήγηση θεραπευτικώς αποτελεσματικής ποσότητας λεπτίνης γίνεται με διάφορους τρόπους συμπεριλαμβανομένων σε φορέα που συνίσταται σε αλληλουχίες νουκλεϊνικών οξέων τα οποία κωδικοποιούν τη λεπτίνη. Οι μέθοδοι της παρούσας εφεύρεσης εξετάζουν τη χορήγηση λεπτίνης, αναλόγων και παραγώγων της σε ασθενείς με επίπεδα λεπτίνης ορού 4 ng/ml ή χαμηλότερα πριν τη λήψη της θεραπευτικής αγωγής.Leptin, its analogs and derivatives are used to treat patients with lipodystrophy. Leptin is effective against lipodystrophic conditions due to either genetic or acquired forms of the disease. A therapeutically effective amount of leptin is administered in a variety of ways including a vector consisting of nucleic acid sequences encoding leptin. The methods of the present invention contemplate the administration of leptin, its analogs and derivatives to patients with serum leptin levels of 4 ng / ml or lower prior to treatment.

CY20131100389T 2001-10-22 2013-05-15 USE OF Leptin for the Treatment of Human Liposuction and the Method for Determining its Affiliation to a Therapeutic Treatment CY1114326T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33639401A 2001-10-22 2001-10-22
EP10165256.8A EP2219031B1 (en) 2001-10-22 2002-10-22 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Publications (1)

Publication Number Publication Date
CY1114326T1 true CY1114326T1 (en) 2016-08-31

Family

ID=58436503

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100389T CY1114326T1 (en) 2001-10-22 2013-05-15 USE OF Leptin for the Treatment of Human Liposuction and the Method for Determining its Affiliation to a Therapeutic Treatment

Country Status (1)

Country Link
CY (1) CY1114326T1 (en)

Similar Documents

Publication Publication Date Title
CY1118849T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
CY1122817T1 (en) NEW ANTI-IL 13 ANTIBODIES AND THEIR USES
CY1105475T1 (en) COMPOSITIONS AND METHODS OF THERAPEUTIC TREATMENT OF NEOPLASMS
CY1119369T1 (en) MEDICAL PREPARATIONS FOR THE THERAPEUTIC TREATMENT OF ALPHA-MILK DISEASE
DK1525219T3 (en) GLP-1 and Methods for the Treatment of Diabetes
CY1117387T1 (en) Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES
EA200000723A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
CY1115782T1 (en) PHARMACEUTICAL COMPOSITIONS FOR CANCER TREATMENT
CY1110405T1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CY1107500T1 (en) USE OF FLUMAZENIL IN THE DEVELOPMENT OF A DRUG FOR THE ALTERNATIVE TREATMENT OF ALCOHOL ADDICTION
DK1444516T3 (en) Use of leptin in the treatment of human lipoatrophy and method for determining a predisposition for this treatment
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
HUP0401903A2 (en) Improved use of et-743 in cancer thereapy
DK0513702T3 (en) Melatonin derivatives for use in the treatment of sleep disorders and for pre-anesthetic medication
ATE354638T1 (en) HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4
CY1109361T1 (en) Substituted 4-Aminocyclohexanols
PT1390371E (en) OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE IN MEDICINES AGAINST TUMORS
HUP0100012A2 (en) Use for macrolides for the treatment of cancer and macular degeneration
NO20023486L (en) Pyrrole-type compounds, compounds containing compounds and their use in the treatment of cancer and viral diseases
CY1107231T1 (en) Substituted 4-Aminocyclohexanol derivatives
YU73301A (en) eNOS MUTATIONS, THEIR USE FOR THE PREPARATION OF GENE THERAPY MEDICINES AND THERAPEUTIC SCREENING PROCEDURES
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
CY1114326T1 (en) USE OF Leptin for the Treatment of Human Liposuction and the Method for Determining its Affiliation to a Therapeutic Treatment
WO2000026362A3 (en) Proteins of the stomatin family and their use as target proteins for pain therapy
DE69800906D1 (en) Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia